Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitro. NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitro.

Princess Takamatsu Symp. 1984;15:277-88. Unique Identifier : AIDSLINE MED/86111569
Mitsuya H; Matsushita S; Yarchoan R; Broder S

Abstract: A recently discovered member of the human T-cell leukemia virus (HTLV) family of retroviruses has been etiologically linked to the acquired immunodeficiency syndrome (AIDS). This virus, which has been designated HTLV-III, is tropic for OKT4+ (helper/inducer) T-cells. Moreover, the virus is cytopathic for these cells. Suramin is a drug used in the therapy of Rhodesian trypanosomiasis and onchocerciasis, and it inhibits the reverse transcriptase of a number of retroviruses including HTLV-III. In the present work, we report our findings that suramin can block the in vitro infectivity and cytopathic effect of HTLV-III at doses that are clinically attainable in human beings. We believe these results may have relevance in planning experimental therapeutic strategies for various diseases associated with members of the HTLV-family of pathogenic human retroviruses.
Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY Cytopathogenic Effect, Viral Human HTLV-BLV Viruses/*DRUG EFFECTS/ENZYMOLOGY/PATHOGENICITY Reverse Transcriptase/ANTAGONISTS & INHIB Suramin/*PHARMACOLOGY/THERAPEUTIC USE T-Lymphocytes/*MICROBIOLOGY JOURNAL ARTICLE REVIEW

KWDacquiredimmunodeficiencysyndrome/KWDdrugtherapycytopathogeniceffect,viralhumanhtlv-blvviruses/KWDdrugeffects/enzymology/pathogenicityreversetranscriptase/antagonists&inhibsuramin/KWDpharmacology/therapeuticuset-lymphocytes/KWDmicrobiologyjournalarticlereview
860530
M8650225

Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .